Association of Azvudine with severe outcomes among hospitalized patients with COVID-19 during an omicron-dominance period in Wuhan, China: a single-center, retrospective, matched cohort study
During a SARS-CoV-2 Omicron variants predominant period, initiation of Azvudine could provide considerable protection against all-cause death, composite severe outcome measure, and result in a significantly shorter nucleic acid conversion time among hospitalized patients with COVID-19. A wider use of Azvudine in clinical settings should be considered.
Authors
- Feng Sun (ORCID: https://orcid.org/0000-0003-4334-6805)
- Hong Cheng (ORCID: https://orcid.org/0000-0001-8182-7082)
- Kailu Wang (ORCID: https://orcid.org/0000-0002-3462-4677)
- Boqiang Chen
- Ziyu Zhai (ORCID: https://orcid.org/0009-0008-7964-2706)
- Suyu Gao
- Wenjing Li (ORCID: https://orcid.org/0000-0002-9905-3836)
- Xinping Wang (ORCID: https://orcid.org/0000-0001-7067-2986)
- Yun Lu
- Zihao Guo (ORCID: https://orcid.org/0000-0001-9432-2227)
- Yanji Zhao
- Zhao Shi
Institutions
- Hong Kong Polytechnic University (HK)
- Xinjiang Medical University (CN)
- Chinese University of Hong Kong (HK)
- Peking University (CN)
- Wuhan University (CN)
- Ministry of Education (RO)
- Zhongnan Hospital of Wuhan University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12879-025-11625-8
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Hubei Province
- National Natural Science Foundation of China
- Tianjin Medical University
- National Science and Technology Major Project